Cobalis Changes Its Trading Symbol From "CBSC" to "CLSC" - Update on Mandatory Share Certificate Exchange

Name	Symbol	Market	Type
Cabana Target Leading Sector Conservative ETF	AMEX:CLSC	AMEX	Exchange Traded Fund

	Price Change	% Change	Price	High Price	Low Price	Open Price	Traded	Last Trade
	0.00	0.00%	21.0027				0	01:00:00

Cabana Target Leading Se... (AMEX:CLSC)
Historical Stock Chart

From May 2019 to May 2024

Click Here for more Cabana Target Leading Se... Charts.

Cobalis Changes Its Trading Symbol From "CBSC" to "CLSC" - Update on Mandatory Share Certificate Exchange IRVINE, Calif., Aug. 27 /PRNewswire-FirstCall/ -- Cobalis Corp. (OTC:CBSC) (BULLETIN BOARD: CBSC) , a pharmaceutical company specializing in the development of anti-allergy medications, announced today that its trading symbol has changed to CLSC effective with the start of trading on Friday August 27, 2004. The symbol change has been done to comply with NASDAQ rules regarding ongoing mandatory share certificate exchange. Concurrently, effective August 27, 2004, the Company's trading will temporarily change to a "when issued" status, symbolized by a "V" added to the end of the ticker symbol (CLSCV), to alert and allow sufficient time for brokerages, clearing houses and investors to exchange the Company's stock certificates for new certificates bearing the new Company name, CUSIP number and names of the beneficial owners. This means that the stock will be trading with open-ended settlement until NASDAQ determines that a sufficient number of the new shares are outstanding and trading in the marketplace. Brokers: please refer to NASDAQ's August 26, 2004 UNIFORM PRACTICE ADVISORY UPC #093-2004. While the stock is in a "when issued" status, the SEC T+3 requirement for settlement of trades within three business days is suspended. As soon as the "when issued" status is removed, the "V" will be removed from the ticker symbol and all unsettled trades will require immediate settlement. All trades will then be required to comply with T+3 settlement rules. MANDATORY SHARE EXCHANGE Effective August 27, 2004, as part of the name change, the CUSIP number change and trading symbol change, all issued and outstanding shares in the name of BioGentech Corp., with the CUSIP number 09063N104, and all issued and outstanding shares in the name of Cobalis Corp., with the CUSIP number 19074Y106, MUST be exchanged for new certificates in the name of Cobalis Corp. with the CUSIP number 19074Y205, and the name of the beneficial owner, or these shares will be void, shall not entitle the certificate holder to any of the rights of a shareholder of the Company, and shall be deemed worthless, non-transferable and non-tradable in any public or private market or exchange after October 12, 2004. For more information regarding the mandatory share exchange, please refer to the Company's Press Release dated August 23, 2004, and/or the Company's website http://www.cobalis.com/. "We thank our shareholders, the transfer agent, and the brokerage community for their patience and support during the mandatory certificate exchange procedure," noted Chas Radovich, Cobalis' President and CEO. "We understand that this is a time-consuming task for all involved, but it is a necessary part of our effort to protect and enhance shareholder value and to ensure the security of all legitimate shareholders of the Company." ABOUT COBALIS CORP. - PREHISTIN(TM) Headquartered in Irvine, California, Cobalis Corp. is an over-the-counter pharmaceutical company. Its flagship product, PreHistin, designed to prevent the primary cause of airborne allergies, is scheduled for Phase III clinical trials in late 2004 and initial marketing in the U.S. will commence upon final FDA marketing approval. The U.S. anti-allergy medication market was $7.2 billion in 2003 and is expected to exceed $10 billion by 2010. PreHistin, "the world's first pre-histamine," has shown in previous clinical studies to modulate the body's level of the protein IgE, reducing the overproduction of histamines, the primary cause of airborne allergy symptoms. Prior studies have shown that the active ingredient in PreHistin appears to have essentially no risks of adverse effects to the general population, including sedation and drowsiness found in many of the allergy products currently available. For further information please visit the website at http://www.cobalis.com/. DATASOURCE: Cobalis Corp. CONTACT: Chaslav Radovich, President & CEO, +1-949-757-0001, or fax, +1-949-757-0979, or , or Bo Cosic, +1-949-757-0001, or cell, +1-714-609-8444, or fax, +1-949-757-0979, or , both of Cobalis Corp. Web site: http://www.cobalis.com/

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

CLSC Cabana Target Leading Sector Conservative ETF